Aliment Pharmacol Ther
-
Publication Venue For
- Editorial: blood biomarkers for advanced liver fibrosis in non-alcoholic fatty liver disease-not a simple choice?. 51:179-180. 2020
- Editorial: awareness and prevention of intravenous iron-induced hypophosphataemia.. 50:609-610. 2019
- Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial.. 49:1205-1213. 2019
- Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors.. 49:1195-1204. 2019
- Editorial: measuring hypervigilance and anxiety in oesophageal disorders.. 47:1559-1560. 2018
- Editorial: platelet transfusions in cirrhosis-do the risks outweigh the unclear benefits?. 47:1553-1554. 2018
- Editorial: diabetes, obesity and clinical inertia-the recipe for advanced NASH. Authors' reply.. 47:1221-1222. 2018
- Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy.. 47:1001-1011. 2018
- Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.. 47:645-656. 2018
- Genetic risk factors for perception of symptoms in GERD: an observational cohort study.. 47:289-297. 2018
- Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.. 47:268-278. 2018
- Letter: inconsistency in reporting of hypophosphatemia after intravenous iron.. 46:641-643. 2017
- The learning curve for interpretation of oesophageal high-resolution manometry: a prospective interventional cohort study.. 45:291-299. 2017
- Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms.. 44:1253-1264. 2016
- Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis.. 44:1183-1198. 2016
- Distal mean nocturnal baseline impedance on pH-impedance monitoring predicts reflux burden and symptomatic outcome in gastro-oesophageal reflux disease.. 44:890-898. 2016
- Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis.. 44:157-169. 2016
- Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers.. 43:356-363. 2016
- Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.. 41:671-685. 2015
- Commentary: the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument.. 37:750. 2013
- Different patterns of decompensation in patients with alcoholic vs. non-alcoholic liver cirrhosis.. 35:1443-1450. 2012
- Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience.. 34:405-407. 2011
- A UK-based cost-utility analysis of radiofrequency ablation or oesophagectomy for the management of high-grade dysplasia in Barrett's oesophagus.. 32:1332-1342. 2010
- Modulation of salivation and heartburn in response to the site of acid infusion in the human oesophagus.. 32:795-800. 2010
- Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome.. 28:239-249. 2008
- Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C.. 27:422-432. 2008